ARS Pharmaceuticals (SPRY) EBIT Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.20% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 269.85% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 76.24% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -36.55% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1,528.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 99.51% |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -29.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.09% |
| Mar 31, 2026 | -61.78% |
| Dec 31, 2025 | -187.86% |
| Sep 30, 2025 | -144.58% |
| Jun 30, 2025 | -210.39% |
| Mar 31, 2025 | -181.81% |
| Dec 31, 2024 | 561.54% |
| Sep 30, 2024 | -20.97% |
| Jun 30, 2024 | 25.54% |
| Mar 31, 2024 | 29.50% |
| Dec 31, 2023 | 33.78% |
| Sep 30, 2023 | -171.16% |
| Jun 30, 2023 | -224.76% |
| Mar 31, 2023 | -163.60% |
| Dec 31, 2022 | -133.12% |
| Sep 30, 2022 | 70.77% |
| Jun 30, 2022 | 74.12% |
| Mar 31, 2022 | 62.41% |
| Dec 31, 2021 | 455.87% |
| Sep 30, 2021 | -179.60% |